In This Article:
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients this week with the Nexalin HALO™.
This significant milestone marks the transition from patient recruitment to active participation in the study, which aims to evaluate Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, delivered through its HALO™ Clarity devices, as a potential treatment for mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in military personnel and the civilian population. The collaboration with UCSD and the San Diego VA underscores Nexalin’s commitment to advancing breakthrough treatment options for patients who are underserved by current therapies.
Mark White, CEO of Nexalin Technology, commented, “We are thrilled to announce that the first patients have now been successfully enrolled and treatment has begun in this important clinical trial at UCSD with the new Nexalin HALO™ headset. This marks a pivotal step forward as we move toward initiating treatments to civilians and veterans struggling with TBI and PTSD. We believe this study will provide critical insights into the efficacy and safety of our innovative DIFS™ technology, helping us further validate its potential as a transformative, drug-free approach to treating mental health disorders.”
The study is designed to gather comprehensive data on the impact of Nexalin’s DIFS™ technology in treating mental health conditions, particularly for veterans and other patient populations who often face limited treatment options. The results from this clinical trial will contribute to Nexalin’s broader regulatory and commercialization strategy as the Company works toward gaining further approvals and expanding the reach of its technology.
“We are pleased to work alongside esteemed researchers at UCSD in collaboration with the San Diego VA as we advance this study,” White continued. “Our goal is to offer new hope to individuals struggling with PTSD, depression, and anxiety, and we look forward to analyzing the findings as the trial progresses.”
The trial follows the recent successful shipment and integration of Nexalin’s HALO™ Clarity devices at UCSD, where they are being used to provide non-invasive, at-home neurostimulation therapy with AI-integrated remote monitoring. Nexalin’s Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS) enable real-time tracking of patient adherence and treatment progress. As the study progresses, additional HALO™ Clarity devices will be deployed to ensure optimal patient coverage and data collection.